Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone hydrochloride injection versus morphine hydrochloride injection for cancer breakthrough pain
ChiCTR-IPR-17013446Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of hydromorphone in breakthrough cancer pain (BTcP) (2 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Pain relief rate. Started Aug 2017; status: recruiting.
02
Drugs
hydromorphone
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on ChiCTR-IPR-17013446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013446.